← Back to patent-cliff list
AZD-8233
Tier C — Watch / tradeAZD-8233
Ionis Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：PCSK9
Indications (approved)：Hyperlipidaemia, Dyslipidaemia, End-stage renal disease, Hypercholesterolaemia
Regional status
US
Phase II
2020-10-28
EU
Phase II
2020-10-28
China
Discontinued
2022-08-24
Japan
Phase II
2021-01-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-8233?
Approved indications include: Hyperlipidaemia, Dyslipidaemia, End-stage renal disease, Hypercholesterolaemia.
When does the AZD-8233 patent expire?
No public expiry year is available for AZD-8233 yet; this page updates once verified.
How do I get a quote for AZD-8233 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06